News

424 Capital exits Reverba after five-year buildout

What's the deal? Private equity firm 424 CapitalDealroom has a profile for this one. Try Dealroom → has sold ReverbaDealroom has a profile for this one. Try Dealroom →, a provider of patient and healthcare professional engagement services to the life sciences industry, in a strategic acquisition. Terms were not disclosed. The buyer was not named.

Why now? 424 Capital first backed the company — then called Health Perspectives GroupDealroom has a profile for this one. Try Dealroom → — in 2021. The exit caps a roughly five-year hold during which 424 reshaped the business.

What's the endgame? 424 invests in tech-enabled services companies across healthcare and energy transition. With Reverba, it aimed to build a broader platform serving pharmaceutical and biotechnology clients across the drug-development and commercialization lifecycle.

What changed? Under 424's ownership, Reverba invested in its leadership, infrastructure, and commercial organization. It acquired Six Degrees Medical, adding medical communications and healthcare professional engagement, an international presence, and earlier reach into drug development. That broadened the company beyond its original patient-engagement focus.

"Reverba represents the type of business we seek to build at 424 — one with a compelling mission and a differentiated market position," said Amit Nagdev, partner at 424 Capital.

Reverba chief executive officer Cheryl Lubbert said 424 "invested alongside us in the people, capabilities, and infrastructure needed to serve our clients and their patients in more meaningful ways."

Baird served as exclusive financial advisor to Reverba, with Whiteman Osterman & Hannah LLP as legal counsel.

The signal: The exit reflects a familiar private equity playbook in healthcare services — buy a niche platform, add bolt-on acquisitions, expand internationally, then sell a scaled market leader. As therapies grow more specialized, demand for firms translating complex science for patients and clinicians continues to draw investor interest.

Read more: prnewswire.com

Image credit: 424 Capital, via PR Newswire

More top stories